Sorry, you need to enable JavaScript to visit this website.

A Gene Therapy Study for Hemophilia B

Gene Therapy, Open-Label, Dose-Escalation Study of SPK-9001 (Adeno-Associated Viral Vector With Human Factor IX Gene) in Subjects With Hemophilia B

Category & Conditions: Rare Diseases
Medicine: fidanacogene elaparvovec (PF-06838435)
ClinicalTrials.gov Identifier (NCT): NCT02484092
Protocol ID: C0371005
    Share
PrintDownload
Open Plain Language Summary Result: Click here